In patients with extensive UC and no prior dysplasia, is chromoendoscopy or standard white‑light colonoscopy with random biopsies preferred at the first surveillance colonoscopy
What is known
- SCENIC consensus and British/European guidelines endorse chromoendoscopy; SCENIC calls it the standard of care over white-light colonoscopy. 1–4 - Chromoendoscopy with targeted biopsies increased dysplasia detection ~4-5 fold per lesion; a meta-analysis showed a 1.8-fold increase and 6% absolute risk increase versus standard-definition white-light with random biopsy. 1,5 - High-definition endoscopy identifies more lesions than standard definition and is itself considered standard of care. 3 - A retrospective study and a Korean HD RCT found no difference in dysplasia detection between chromoendoscopy and white-light colonoscopy with random biopsies. 2,5
What is unknown / caveats
- Guidelines endorse chromoendoscopy as standard of care - Retrospective and HD-RCT data show no detection benefit over white-light with random biopsies - Much of the chromoendoscopy advantage was demonstrated against standard-definition, not high-definition, white light - Clinical impact of higher detection on patient outcomes described as largely unknown - Excerpts do not specifically address the first surveillance exam or patients without prior dysplasia - The added value of chromoendoscopy over high-definition white-light colonoscopy is questionable and not resolved by the excerpts.
## References
1. East JE. Colonoscopic Cancer Surveillance in Inflammatory Bowel Disease: What's New Beyond Random Biopsy?. Clin Endosc. 2012. PMID: 22977816.
2. Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas V, Mouli VP, Kedia S, Dhingra R, Pradhan R, Kumar NS, Yadav DP, Makharia G, Ahuja V. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res. 2016. PMID: 27433149.
3. Bhama AR, Kapadia MR. Management of Dysplasia in Ulcerative Colitis. J Laparoendosc Adv Surg Tech A. 2021;31:855-860. PMID: 34252316.
4. Hata K, Kishikawa J, Anzai H, Shinagawa T, Kazama S, Ishii H, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J, Tanaka T, Nishikawa T, Otani K, Yasuda K, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Watanabe T. Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. Dig Endosc. 2016. PMID: 26096182.
5. Ahuja V, Hilmi I, Ye BD, Ling KL, Ng SC, Leong RW, Kumar P, Khoo XH, Makharia GK, Sollano J, Pisespongsa P, Mustaffa N, Banerjee R, Leow AH, Raja Ali RA, Chuah SW, Palaniappan S, Ooi CJ, Leung WK. Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease. J Gastroenterol Hepatol. 2024;39(8):1500-1508. PMID: 38725188.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (moderate). After a diagnosis of low-grade dysplasia, guidelines (SCENIC/AGA/BSG/ECCO) advise a SHORT-interval repeat examination, typically 3-6 months, not simply annual.
_Why this matters:_ Stating 'annual surveillance' as the interval after LGD delays re-examination of the highest-risk group.
_Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper. Not generated by the RAG._
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes